AbCellera Biologics Inc (NASDAQ:ABCL) has a beta value of 0.50 and has seen 0.33 million shares traded in the recent trading session. The company, currently valued at $639.18M, closed the recent trade at $2.14 per share which meant it gained $0.05 on the day or 2.63% during that session. The ABCL stock price is -121.96% off its 52-week high price of $4.75 and 3.74% above the 52-week low of $2.06. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.35 million shares traded. The 3-month trading volume is 4.10 million shares.
The consensus among analysts is that AbCellera Biologics Inc (ABCL) is Buy stock at the moment, with a recommendation rating of 1.25. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 9 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.14.
AbCellera Biologics Inc (NASDAQ:ABCL) trade information
Sporting 2.63% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the ABCL stock price touched $2.14 or saw a rise of 11.57%. Year-to-date, AbCellera Biologics Inc shares have moved -26.79%, while the 5-day performance has seen it change -11.36%. Over the past 30 days, the shares of AbCellera Biologics Inc (NASDAQ:ABCL) have changed -8.33%. Short interest in the company has seen 22.79 million shares shorted with days to cover at 4.6.
Wall Street analysts have a consensus price target for the stock at $5, which means that the shares’ value could jump 57.2% from the levels at last check today. The projected low price target is $5.0 while the price target rests at a high of $5.0. In that case, then, we find that the latest price level in today’s session is -133.64% off the targeted high while a plunge would see the stock gain -133.64% from the levels at last check today.
AbCellera Biologics Inc (ABCL) estimates and forecasts
The company’s shares have lost -17.50% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -8.82%.
7 analysts offering their estimates for the company have set an average revenue estimate of 7.12M for the current quarter. 7 have an estimated revenue figure of 6.71M for the next ending quarter. Year-ago sales stood 9.95M and 7.32M respectively for this quarter and the next, and analysts expect sales will shrink by -28.43% for the current quarter and -8.82% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -107.74% over the past 5 years. Earnings growth for 2025 is a modest -10.53% while over the next 5 years, the company’s earnings are expected to decrease by -9.14%.
ABCL Dividends
AbCellera Biologics Inc is expected to release its next earnings report on 2025-Feb-26 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
AbCellera Biologics Inc (NASDAQ:ABCL)’s Major holders
Insiders own 22.88% of the company shares, while shares held by institutions stand at 42.27% with a share float percentage of 54.81%. Investors are also buoyed by the number of investors in a company, with AbCellera Biologics Inc having a total of 197.0 institutions that hold shares in the company. The top two institutional holders are BAKER BROS. ADVISORS LP with over 27.53 million shares worth more than $81.48 million. As of 2024-06-30, BAKER BROS. ADVISORS LP held 9.3556% of shares outstanding.
The other major institutional holder is BAILLIE GIFFORD & CO, with the holding of over 21.91 million shares as of 2024-06-30. The firm’s total holdings are worth over $64.86 million and represent 7.4472% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are SMALLCAP WORLD FUND INC and iShares Trust-iShares Biotechnology ETF. As of Dec 31, 2024, the former fund manager holds about 2.53% shares in the company for having 7.54 shares of worth $16.32 million while later fund manager owns 1.31 shares of worth $2.84 million as of Feb 28, 2025, which makes it owner of about 0.44% of company’s outstanding stock.
